

RTP On Demand: Current Controversies and Emerging Data Sets
in Follicular Lymphoma and Chronic Lymphocytic Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III RELEVANCE study is comparing _____ to _____ for patients with previously untreated follicular lymphoma.
 - a. Rituximab; lenalidomide
 - b. Lenalidomide; R-CHOP
 - c. Rituximab; rituximab/bendamustine
 - d. Rituximab/lenalidomide; rituximab/chemotherapy
2. In the CLL11 study evaluating obinutuzumab/chlorambucil or rituximab/chlorambucil versus chlorambucil alone for patients with chronic lymphocytic leukemia (CLL) and comorbidities, the objective response rate with obinutuzumab/chlorambucil reached 75%.
 - a. True
 - b. False
3. A Phase II study of single-agent ibrutinib for patients with CLL with 17p deletion reported nodal responses in excess of 80%.
 - a. True
 - b. False
4. In the BRIGHT study evaluating front-line bendamustine in combination with rituximab (BR) versus rituximab with cyclophosphamide/vincristine/prednisone (R-CVP) or R-CHOP for patients with advanced indolent non-Hodgkin lymphoma or mantle-cell lymphoma, the most common adverse events reported in the BR arm included which of the following symptoms?
 - a. Nausea
 - b. Fatigue
 - c. Lymphopenia
 - d. All of the above